Subgroup identification in clinical trials via the predicted individual treatment effect

por Ballarini, Nicolás M., Rosenkranz, Gerd K., Jaki, Thomas, König, Franz, Posch, Martin
Publicado 2018

Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label,...

por Bailey, Donald B., Berry-Kravis, Elizabeth, Wheeler, Anne, Raspa, Melissa, Merrien, Florence, Ricart, Javier, Koumaras, Barbara, Rosenkranz, Gerd, Tomlinson, Mark, von Raison, Florian, Apostol, George
Publicado 2015

Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents

por Hagerman, Randi, Jacquemont, Sebastien, Berry-Kravis, Elizabeth, Des Portes, Vincent, Stanfield, Andrew, Koumaras, Barbara, Rosenkranz, Gerd, Murgia, Alessandra, Wolf, Christian, Apostol, George, von Raison, Florian
Publicado 2018

Applicability and added value of novel methods to improve drug development in rare diseases

por Mitroiu, Marian, Rengerink, Katrien Oude, Pontes, Caridad, Sancho, Aranzazu, Vives, Roser, Pesiou, Stella, Fontanet, Juan Manuel, Torres, Ferran, Nikolakopoulos, Stavros, Pateras, Konstantinos, Rosenkranz, Gerd, Posch, Martin, Urach, Susanne, Ristl, Robin, Koch, Armin, Loukia, Spineli, van der Lee, Johanna H., Roes, Kit C. B.
Publicado 2018